Howard I. Scher, MD, of Memorial Sloan Kettering Cancer Center, discusses the updated criteria that will guide clinical trial design and conduct for therapeutics being tested in castration-resistant prostate cancer (Abstract 5000).
Leonard Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses how the cost of care affects behavior and decision-making on the part of patients and oncologists.
Patrick Schöffski, MD, of the University Hospital Leuven, discusses a phase III study in which he and his colleagues found, for the first time in soft-tissue sarcomas, a significant overall survival benefit of a single agent compared to a standard treatment (Abstract LBA10502).
Gregory T. Armstrong, MD, MSCE, of St. Jude Children's Research Hospital, discusses the findings of a landmark survivorship study (Abstract LBA2).
Ruben A. Mesa, MD, of the Mayo Clinic, discusses pacritinib and its significant efficacy in myelofibrosis (Abstract LBA7006).
Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute discusses the EnzaMet and EnzaRad study designs, eligibility requirements, and endpoints (Abstracts TPS5077 and TPS5078).
